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Ulcerative colitisBackground/aims: High levels of pro-inﬂammatory cytokines are linked to inﬂammatory bowel disease (IBD).
The transcription factor Caudal-related homeobox transcription factor 2 (CDX2) plays a crucial role in differen-
tiation of intestinal epithelium and regulates IBD-susceptibility genes, including meprin 1A (MEP1A). The aim
was to investigate the expression of CDX2 andMEP1A in colitis; to assess if they are regulated by tumor necrosis
factor-α (TNF-α), and ﬁnally to reveal if CDX2 is involved in a TNF-α-induced down-regulation of MEP1A.
Methods: Expression of CDX2 and MEP1A was investigated in colonic biopsies of ulcerative colitis (UC) patients
and in dextran sodium sulfate (DSS)-induced colitis. CDX2 protein expression was investigated by immunoblot-
ting and immunohistochemical procedures. CDX2 and MEP1A regulation was examined in TNF-α-treated
Caco-2 cells by reverse transcription-polymerase chain reaction and with reporter gene assays, and the effect
of anti-TNF-α treatment was assessed using inﬂiximab. Finally, in vivo CDX2–DNA interactions were investi-
gated by chromatin immunoprecipitation. Results: The CDX2 andMEP1AmRNA expression was signiﬁcant-
ly decreased in active UC patients and in DSS-colitis. Colonic biopsy specimens from active UC showed
markedly decreased CDX2 staining. TNF-α treatment diminished the CDX2 and MEP1A mRNA levels, a de-
crease which, was counteracted by inﬂiximab treatment. Reporter gene assays showed signiﬁcantly reduced
CDX2 andMEP1A activity upon TNF-α stimulation. Finally, TNF-α impaired the ability of CDX2 to interact and ac-
tivate its own, as well as theMEP1A expression. Conclusions: The present results indicate that a TNF-α-mediated
down-regulation of CDX2 can be related to suppressed expression ofMEP1A during intestinal inﬂammation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Inﬂammatory bowel disease (IBD), of which ulcerative colitis (UC)
and Crohn's disease (CD) are the two main entities, is characterized
by an abnormal immune response to antigens of the intestinal luminal
content leading to a persistent inﬂammatory state. Clinical symptomslated homeobox transcription
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rights reserved.of IBD include abdominal pain, diarrhea, rectal bleeding, and weight
loss [1]. The etiology of IBD is unknown, but involves a complex inter-
play of environmental factors including the gut microbiota, as well as
genetics affecting the intestinal barrier function. Thus, the intestinal
barrier is pivotal for the maintenance of intestinal homeostasis, and a
linkage between the key signaling pathways involved in inﬂammation
and regulators of homeostasis is often observed [2].
One of the key factors involved in maintaining the intestinal epithe-
liumhomeostasis is the Caudal-related homeobox transcription factor 2
(CDX2). CDX2 is an intestine-speciﬁc transcription factor, which is
essential for the regulation of genes related to epithelial functions
[3–8]. A conditional knock-out of the murine Cdx2 gene results in a
disorganization in the differentiation of the intestinal epithelium, as
the colonocytes differentiate into a gastric rather than into an intestinal
phenotype [9]. Therefore, CDX2 is a crucial regulator of intestinal ep-
ithelial function, controlling the balance between differentiation
and proliferation of intestinal epithelial cells (IECs) [10]. Given the
importance of CDX2 in regulating numerous intestinal genes on the
one hand, and preserving intestinal homeostasis on the other hand, it
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unbreached intestinalmucosa. In fact, several studies have reported that
Hepatocyte nuclear factor 4 alpha (HNF4α), Meprin 1A (MEP1A), Peptide
transporter 1 (PEPT1), Claudin-2 (CLDN2), andMucin 2 (MUC2) are sus-
ceptible genes associated with IBD [11–15] and experimental colitis
[16–18]. Interestingly, all these genes are CDX2-targets [19–22].
Until now only limited efforts have been allocated into the inves-
tigation of CDX2 in relation to intestinal inﬂammation. In one recent
study, a diminished CDX2 expression was revealed in UC [23]. On
the contrary, another study did not ﬁnd any correlation between
CDX2 positive cells and the degree of inﬂammation in UC [24]. Thus,
the source of CDX2 expression in the inﬂamed mucosa of IBD patients
remains to be investigated. Further, we have earlier demonstrated that
MEP1A, a membrane-associated protein that is expressed by IECs and
hydrolyzes a variety of peptide and protein substrates [25,26], is a direct
target gene of CDX2 [19], and recently a down-regulation of MEP1A in
UC has been reported [12]. Additionally, Cdx2+/−mice or mice lacking
Mep1a developed more severe inﬂammation than wild-type mice in
response to dextran sodium sulfate (DSS)-induced colitis [12,17,27].
To date, the regulation of CDX2 in mucosal inﬂammation is rather
unclear, except that one study has reported that CDX2 expression is
repressed by tumor necrosis factor-α (TNF-α) signaling [28]. TNF-α
is a pro-inﬂammatory cytokine, found at increased concentrations in
the inﬂamed intestines of UC and CD [29,30], and neutralizing the
biological activity of TNF-α with inﬂiximab (IFX), a chimeric monoclo-
nal antibody against human TNF-α, may induce clinical remission in IBD
[31]. Thus we speculated that an increased amount of TNF-α in inﬂamed
intestinal mucosa might suppress MEP1A gene expression at the tran-
scriptional level by inhibiting CDX2 regulation. To address this question,
we aimed to investigate the correlation between TNF-α and the expres-
sion of CDX2 and MEP1A in intestinal inﬂammation. We analyzed the
inﬂuence of TNF-α on the expression and activity of CDX2 and MEP1A
in inﬂammation, and further studied the effect of anti-TNF-α treatment
with IFX using in vitro experiments.2. Material and methods
2.1. Patients and tissue samples
Twenty-two patients underwent a routine colonoscopy due to their
clinical condition andwere included into the study: six UC patientswith
active disease and eight with quiescent disease, together with eight
healthy controls (i.e. patients undergoing an endoscopydue to gastroin-
testinal symptoms but where all clinical and paraclinical investigations
subsequently turned out to be normal). The disease activity of all UC
patients were before the colonoscopy graded in accordance with Mayo
score [32]: a score≤2 as the disease in remission, and >2 (max. 12) as
active stages of the disease. Patient characteristics are shown in Table 1.
Nopregnant or breastfeedingwomen, individualswith other inﬂamma-
tory diseases, an anamnesis of cancer or psychiatric disorders were
included, and none had an infection within the last 2 weeks. No selec-
tionwasmade for age, gender, or disease duration. None of the included
patients had received IFX or recent (within 14 days) use of antibiotics.
Six biopsies each of approximately 15 mg each were obtained from
the descending colon in each patient during the colonoscopy.Table 1
Patient characteristics.
Controls Quiescent UC Active UC
n 8 8 6
Gender (male/female) 5/3 1/7 3/3
Age—years, median (IQR) 52 (43–60) 54 (44–58) 42 (37–50)
Years with disease (b10 yrs/>10 yrs) – 6/2 4/2
UC, ulcerative colitis; IQR, interquartile range.The study was approved by the Scientiﬁc Ethics Committee of the
Capital Region of Denmark. All patients gave their informed consent
to participate in the study.2.2. Cell culture and treatment
The human colonic Caco-2 cells (American Tissue Type Culture
Collection; Rockville, MD, USA) were maintained and grown as previ-
ously described [33]. Caco-2 cells were seeded in 24-well plates
(NUNC Brand, Thermo Fisher, Rochester, NY, USA) and grown to >95%
conﬂuence. Cells were then stimulated in medium with or without
interferon-γ (IFN-γ) (10 nM; Sigma-Aldrich, St. Louis, MO, USA) or
TNF-α (10 nM; R&D Systems, Minneapolis, MN, USA) in the presence
or absence of IFX (100 μg/ml; Centocor Ortho Biotech Inc., Horsham,
PA, USA). The cells were harvested after 24 h.2.3. RNA extraction and quantitative RT-PCR
Total RNA from isolated colonocytes from tissue samples were
isolated and quantitative reverse-transcription polymerase chain re-
action (qRT-PCR) was performed as previously described [34]. Target
gene expressions were calculated by their ratios to the housekeeping
reference gene human Ribosomal Protein Large P0 (RPLP0) or mouse
β-actin, which were ampliﬁed in parallel reactions. Sequences of the
primers are listed in Supplementary Table S1. The cycling conditions
are available upon request.2.4. Protein extraction and immunoblotting
Colonocyteswere isolated as earlier described in detail [35]. Primary
colonocytes were lysed with RP1 lysis buffer (Macherey-Nagel, Düren,
Germany) and protein extractswere obtained as earlier described in de-
tail [34]. The primary antibodies were: CDX2 (1:1000; mousemonoclo-
nal; BioGenex Laboratories Inc., Fremont, CA, USA), and Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (1:20,000; mouse monoclonal;
Fitzgerald, Concord, MA, USA).2.5. Transient transfection, treatment and luciferase assays
For transient transfection of promoter constructs, Caco-2 cells
were seeded in 24-well plates at a density of 5×104 cells/well and
transiently transfected the following day using ExGen500 in vitro
transfection reagent (Fermentas, St. Leon-Rot, Germany). In treatment
experiments, themediumwas changed 24 h after transfection, washed,
and subsequently stimulated with or without TNF-α (10 nM) for the
next 24 h. The constructs containing the human CDX2 or MEP1A pro-
moter have earlier been described [19]. A glycogen synthase kinase-
3β (GSK3β) promoter construct (pGL4-GSK3β) containing the region
−1173 to −128 was used as a non-TNF-α responsive promoter. For
co-transfections, full-length CDX2 (a CDX2 expressing plasmid),
CDX2Δ55–136 (an expression vector with a deleted CDX2 activation
domain between amino acids 55 and 136); both kindly provided by
Dr. John P. Lynch [36], empty pcDNA3.1 (+) expression vector, or a
combination of these expression vectors were added together with
0.1 μg pCMV-lacZ (as internal transfection control) and normalized to
a total amount of 0.3 μg DNA/well with pBluescript SK+ plasmid.
Forty-eight hours post-transfection, cells were harvested and lysed,
and luciferase and β-galactosidase activities were determined using
the Dual Light system (Perkin Elmer, Waltham, MA, USA) according to
manufacturer's instructions. Each luciferase activity was normalized to
β-galactosidase activity. Reporter gene activities of both treated and
untreated samples were normalized to the activity of the promoter-
less pGL4-Basic vector and presented as fold induction.
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Twenty-four female BALB/cAcNTac mice (8–10 week old) were
obtained from Taconic (Ry, Denmark). All the mice were housed under
pathogen-free conditions with free access to tap water and pelleted
food in a 12-hour light/dark cycle. Mice were kept for >2 weeks before
entering the study. The Novo Nordisk ethical review committee and
the Danish Animal Experiments Inspectorate reviewed and approved
all experimental procedures.
During the experiment, daily prepared tap water supplemented
with 4% (wt/vol) DSS (MW 36–50 kDa; ICN Biomedicals, Aurora,
OH, USA) was administrated for 5 days, and then tap water ad libitum.
Scoring of the mice was performed using a disease activity index
(DAI) [37] according to the parameters outlined in Supplementary
Table S2. A group of DSS mice was killed on day 0, day 3, and day 7
post-treatment, and a control group (no DSS) was killed at the end of
the experiment (6 mice in each group). Total RNA was extracted from
proximal and distal colon, and qRT-PCR was performed as described
above.
For histopathological analyses, tissues were ﬁxed in 4% (wt/vol)
paraformaldehyde and embedded in parafﬁn for sectioning. Tissue
sections were cut at 3–4 μm thin slices and stained with H&E or Alcian
blue periodic acid-Schiff (AB-PAS). The same pathologist performed
all evaluations, and samples were masked to ensure a blind fashion
study. The extent of colonic changes were scored semi-quantitatively:
no (0), mild (1), moderate (2), marked (3), and severe (4) based on
four different categories, i.e., ulceration, inﬁltration of inﬂammatory
cells, crypt distortion, and loss of mucin stain. Thus, the total score
ranged from 0 to 16.Fig. 1. CDX2 activates MEP1A expression in Caco-2 cells. Caco-2 cells were transfected
with the pGL4-MEP1A reporter plasmid alone or together with full-length CDX2 or
truncation CDX2Δ55–136 mutant expression vector. Values are presented as relative to the
promoter-less pGL4-Basic empty vector (EV) and presented as fold induction. Represented
as medians with interquartile ranges (n=4), *pb0.05) (Mann–Whitney U-test).2.7. Chromatin immunoprecipitation (ChIP) assay
Caco-2 cells were cultured for 5 days after conﬂuence and stimu-
lated with TNF-α (10 nM) or left untreated for 24 h. The cells were
cross-linked and sonicated as previously described [33]. For each
immunoprecipitation, 300 μl of cross-linked sonicated sample was
diluted with 1.2 ml ChIP buffer (1% Triton X-100, 150 mM NaCl,
2 mM EDTA, 20 mM Tris–HCl pH 8.0, and 1 μl/ml protease inhibitors
(Sigma-Aldrich)). From each sample, 15 μl corresponding to 1% of
the input DNA was reserved as input control. Immunoprecipitation
was performed overnight at 4 °C with an antibody speciﬁc for either
human CDX2 (65.2 μg/ml, mousemonoclonalα-CDX2; BioGenex Labo-
ratories Inc.) or an inﬂuenza hemagglutinin (HA) protein (200 μg/ml,
rabbit polyclonal α-HA; Santa Cruz Biotechnology Inc., Heidelberg,
Germany) used as a negative control. Immunocomplexes were recov-
ered with 50 μl protein A/Gmagnetic beads (Invitrogen A/S, Darmstadt,
Germany) overnight at 4 °C on rotation. The beads were washed twice
inWash Buffer 1 (0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate,
150 mM NaCl, 1 mM EGTA, 2 mM EDTA, and 20 mM Tris–HCl pH 8.0),
twice inWash Buffer 2 (0.1% SDS, 1% Triton X-100, 0.1% sodium deoxy-
cholate, 500 mM NaCl, 1 mM EGTA, 2 mM EDTA, and 20 mM Tris–HCl
pH 8.0), once inWash Buffer 3 (0.25 M LiCl, 0.5% sodium deoxycholate,
0.5% NP-40, 0.5 mM EGTA, 1 mM EDTA, and 10 mM Tris–HCl pH 8.0),
and ﬁnally twice in TE buffer (10 mM Tris–HCl pH 8.0 and 1 mM
EDTA). Immunocomplexes were eluted with 300 μl fresh elution buffer
(1% SDS, 0.1 M NaHCO3, and 200 mM NaCl) and incubated for 30 min
on a heat block at 65 °C. DNA–protein cross-links were reversed by
incubating samples overnight at 65 °C in 12 μl 5 M NaCl. The samples
were further incubated for 30 min at 37 °C with 240 ml TE buffer,
1.5 ml of 20 mg/ml glycogen, and 10 μl of 10 mg/ml RNase A (Invitrogen)
to eliminate RNA. Recovered material was treated with 5 μl of 20 mg/ml
proteinase K (Qiagen, Hilden, Germany) at 55 °C for 2 h, and the reaction
was stopped by 55 μl of 4 M LiCl. The DNA was ﬁnally recovered by
buffered phenol–chloroform extraction (pH 7.9; Invitrogen), and ethanol
precipitated. The DNA was resuspended in 20 μl dH2O.Veriﬁcation of enrichment due to immunoprecipitation was done
with qPCR using a Stratagene Mx3000P thermocycler (Stratagene, La
Jolla, CA, USA) according to the manufacturer's protocol with Brilliant
SYBRGreenQPCRMasterMix Kit (Stratagene). The primers used to am-
plify the human genomic sequences of CDX2 andMEP1A at CDX2-target
loci were previously described [19]. Quantiﬁcation of the ChIP DNAwas
performed using the method described [38].
2.8. Immunohistochemistry (IHC)
Four-micrometer sections of formalin ﬁxed and parafﬁn-embedded
biopsieswere deparafﬁnized and pretreated using EnVision FLEX Target
Retrieval Solution (DAKO, Glostrup, Denmark). The tissue sectionswere
processed in an automatic immunohistochemistry (IHC) staining ma-
chine using the standard protocols with DAKO Autostainer LINK. The
following antibodies were used: cytokeratin 20 (CK20) (1:50, Ks20.8,
DAKO M7019) and CDX2 (FLEX CDX2, MxH (DAK CDX2)). The slides
were counterstained with Mayer's hematoxylin before viewing. Cyto-
plasmatic staining was considered positive for CK20 whereas nuclear
staining was required for CDX2 to be positive.
2.9. Statistical methods
Values are presented as medians (interquartile ranges). Groups were
compared using the Mann–Whitney U-test. Two-sided p-valuesb0.05
were considered signiﬁcant. Non-parametrical statistical analysis was
done using GraphPad Prism version 5 (GraphPad Software, SD).
3. Results
3.1. The MEP1A gene is a primary target of CDX2 activity
We have recently demonstrated that CDX2 is necessary to maintain
expression of MEP1A in mammalian cells [19]. CDX2-speciﬁc shRNAs
signiﬁcantly suppressed the expression of MEP1A transcript by more
than 40% in Caco-2 cells. In the same study, we also noted that the
MEP1A promoter activity was nearly 5-fold decreased in CDX2 knock-
down cells [19]. To better assess the relationship between CDX2 func-
tion and MEP1A gene expression, Caco-2 cells were co-transfected
with the MEP1A promoter construct along with full-length CDX2 or a
CDX2Δ55–136 mutant expression vector. Co-transfection with the
expression vector encoding full-length CDX2 led to a signiﬁcantly
3-fold stimulation (pb0.05) of the transcriptional activity of the MEP1A
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truncation mutant resulted in a nearly 30% reduced activity (pb0.05)
compared to the MEP1A promoter alone, and almost a 4-fold decrease
(pb0.05) compared to the activity induced by the full-length CDX2
expression vector (Fig. 1).3.2. CDX2 and MEP1A expression are correlated in patients with active
UC
To determine whether CDX2 and MEP1A expression were corre-
lated with disease activity, mRNA levels from endoscopic biopsies in
UC patients and healthy controls were measured using qRT-PCR. To
eliminate that any changes in mRNA expression in inﬂamed mucosa
is a result of a reduced number of colonocytes in the biopsies, the
mRNA expressions where determined as ratios to CK20 mRNA (an
established IEC marker). Relative mRNA levels of CK20 were found
to remain unchanged in colonic mucosa from healthy patient samples,
quiescent UC, and active UC (data not shown), indicating a relative
unaffected number of colonocytes in the three groups. Patients withFig. 2. CDX2 and MEP1A expression are reduced in active UC. Relative mRNA levels of (A) CD
and active UC (n=6) patients. Values were normalized to RPLP0 and ratios of CDX2, MEP1
healthy patients. Represented as medians, **pb0.01; ***pb0.001 (Mann–Whitney U-test).
as an internal loading control. Densitometric analysis of CDX2 protein level is shown. D
(n=3), *pb0.05. (E) Immunohistochemical staining of CDX2 protein expression in healthy
and are markedly decreased in active UC. CK20 staining represents epithelial cells. The exainactive UC had CDX2 mRNA levels similar to those found in healthy
samples (Fig. 2A). In contrast, expression of CDX2 was signiﬁcantly
decreased (pb0.01) in colonocytes in active UC. As we have found
that MEP1A is a direct target gene of CDX2, the expression status
of MEP1A, was assessed by qRT-PCR. The MEP1A gene transcript was
like CDX2 levels signiﬁcantly reduced in active UC versus healthy
controls (pb0.01), and MEP1A mRNA showed a signiﬁcant difference
between quiescent and active UC (pb0.001; Fig. 2B). The inﬂamed
colon, however, exhibited a signiﬁcant increased TNF-α mRNA ex-
pression as compared to healthy samples and quiescent UC patients
(pb0.001, respectively) (Fig. 2C).
As shown in Fig. 2D, CDX2 protein abundance was signiﬁcantly
decreased in active UC. Quantiﬁcation by densitometry scanning
showed ~40% reduction in CDX2 protein level in active UC samples.
Consistent with these data, the protein expression of CDX2 and
CK20 determined by IHC displayed a positive expression in all IECs
in healthy patient samples and in quiescent UC (Fig. 2E). In active
UC patients, CDX2 expression was markedly decreased, while CK20-
positive cells were unchanged (Fig. 2E), indicating that the down-
regulation of CDX2 is caused by the disease activity.X2, (B) MEP1A, and (C) TNF-α in healthy patient samples (n=8), inactive UC (n=8),
A, or TNF-α to CK20 (a marker of epithelial cells) mRNA levels where compared with
(D) Western blot analysis using an antibody speciﬁc for either CDX2 or GAPDH used
ata are presented as intensity of the CDX2 protein relative to the GAPDH intensity
, inactive UC and active UC patient samples show that CDX2 is localized to colonocytes
mination was performed by using the sections from three different individuals.
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induced colitis
The mice were treated with DSS for 5 days and then returned to
normal drinking water to allow a 7-day period of mucosal recovery.
Disease activity (incl. weight loss, diarrhea and fecal blood) and histo-
pathological score peaked 3 days after discontinuing DSS treatment
and clear signs of remission were observed at day 7 (Table 2). As
with the human samples, the mRNA values where investigated and
expressed as ratios to Ck20 mRNA. In contrast to the human samples,
mice Ck20 mRNA levels were reduced at day 0 in both proximal and
distal colon (data not shown). Cdx2 mRNA expression in the proximal
colon was reduced (pb0.05) at day 0 compared to untreated control
mice, and a trend toward up-regulation at day 7 was observed (Fig. 3A,
left). On day 0 and day 3, there was a signiﬁcant decrease (pb0.05, re-
spectively) in the Cdx2 transcript in the distal colon versus untreated
controls (Fig. 3B, left).
In both proximal and distal colon of mice the Mep1a mRNA levels
were signiﬁcantly decreased at day 0 and day 3 relative to untreated
mice (pb0.01, respectively) (Fig. 3A and B, middle). Furthermore, at
day 7 the Mep1a mRNA expression was signiﬁcantly up-regulated
(pb0.01) in the proximal colon compared to day 3.Mep1a expression
in the distal murine colon was signiﬁcantly down-regulated at day 7
(pb0.05) compared to controls, yet, compared to the mRNA levels
of day 3 the expression was signiﬁcantly increased (pb0.01; Fig. 3B,
middle).
TNF-αmRNA transcripts were also measured to conﬁrm that acute
inﬂammation occurred following DSS treatment. From the start of the
recovery procedure (day 0), both proximal and distal colon displayed
comparable TNF-α mRNA levels signiﬁcantly increased compared to
untreated mice (pb0.01, respectively) (Fig. 3A and B, right). However,
after 7 days of recovery (day 7) the TNF-α mRNA in the proximal
colon was similar to the levels in the control mice, whereas the distal
colon still had signiﬁcantly increased TNF-α expression compared
to control mice (pb0.05) (Fig. 3A and B, right) with a trend towards
down-regulation versus day 3.3.4. Inﬂuence of pro-inﬂammatory cytokines on CDX2 and MEP1A
expression
To determine whether pro-inﬂammatory TNF-α or IFN-γ cytokines
inﬂuence the endogenous CDX2 and MEP1A mRNA expression, Caco-2
cells were stimulated with either IFN-γ or TNF-α for 24 h. A signiﬁcant
repression of CDX2 and MEP1A mRNA expression (pb0.001, respec-
tively) was observed when cells were treated with TNF-α (Fig. 4A and
B). However, treatment with IFN-γ had no effect on CDX2 and MEP1A
transcripts. IL-8 is a pro-inﬂammatory component produced in responseTable 2
Characteristics of mice included into the study.
Controls D
Length of colon—cm, median (IQR) 10.9 (10.63;11.80) 9
Weight of colon—g, median (IQR) 0.28 (0.26;0.29) 0
Body weight change—%, median (IQR)b 3.37 (1.47;4.04) -
Blood in stools 0/6 3
Diarrhea 0/6 3
DAI score—median (IQR) 0 (0;1.0) 2
Histopathological score—median (IQR)
Distal colon 0 (0;2.5) 2
Proximal colon 0 (0;0.3) 1
DSS, dextran sodium sulfate; DAI, disease activity index; IQR, interquartile range.
a The number of days after the termination of DSS treatment.
b Percentage weight change was calculated by using the initial body weight of the indivito injury and is a well-known target of IFN-γ or TNF-α. In Fig. 4C, mRNA
measurements in the media of IFN-γ or TNF-α treated cells showed a
signiﬁcant increase in the IL-8 mRNA by 1.5- and 5.5-fold (pb0.01 and
pb0.001, respectively) compared with the untreated cells.
Having identiﬁed that TNF-α reduces CDX2 and MEP1A mRNA in
colonic epithelial cells, we subsequently investigated whether block-
ing of TNF-αwith anti-TNF-α antibody (IFX) could reverse this effect.
This antibody was chosen, as it has been the most commonly used
TNF-α inhibitor in treatment of inﬂammatory diseases. As shown in
Fig. 4A and B, co-treatment of cells with TNF-α and IFX signiﬁcantly
increased CDX2 and MEP1A expression (pb0.01 and pb0.001, respec-
tively) as compared to cells treated with TNF-α alone. Conversely,
TNF-α blockade by IFX signiﬁcantly decreased IL-8 (pb0.001; Fig. 4C)
indicating that IFX effectively reversed the effect of TNF-α in these
experimental conditions.3.5. Inﬂuence of TNF-α on CDX2 and MEP1A promoter activities and
binding of CDX2
Since the analysis of mRNA expressions indicated transcriptional
down-regulation by TNF-α, CDX2 and MEP1A promoter activities were
subsequently investigated by means of reporter gene assays in Caco-2
cells. Therefore, luciferase reporter gene assayswas performed by trans-
fecting IECs with constructs containing regions of the human CDX2 pro-
moter, CDX2 promoter/enhancer, and the MEP1A promoter (Fig. 5A).
It was observed that TNF-α signiﬁcantly decreased the CDX2 promoter
activity with ~30% (pb0.05), whereas, the reporter gene activity driven
by the CDX2 promoter/enhancer construct decreased almost 50%
(pb0.05). Furthermore, the luciferase activity in the MEP1A promoter
construct was signiﬁcantly repressed with ~50% in the presence of
TNF-α (pb0.05; Fig. 5A). TNF-α treatment did not affect the GSK3β
promoter construct, indicating that the repression observed for
CDX2 and MEP1A promoter activities is not a general transcriptional
down-regulation in response to TNF-α.
To investigate the effect of TNF-α on the physical interaction be-
tween CDX2 and the gene regulatory regions on CDX2 andMEP1A, we
performed a ChIP assay. Chromatin-protein complexes from the
untreated and TNF-α-treated cells were immunoprecipitated with
a CDX2 antibody or a HA antibody (negative control). The amount of
co-immunoprecipitated CDX2 5′ promoter, CDX2 3′ enhancer, and
MEP1A 5′ promoter DNA was measured by qPCR. The in vivo binding of
CDX2 to the 5′ and 3′ regulatory elements of the CDX2 gene decreased
signiﬁcantly (pb0.05) in cells treated with TNF-α (Fig. 5B). Further-
more, the binding of CDX2 protein to the MEP1A promoter region
was signiﬁcantly suppressed (pb0.05), as shown by reduced co-
immunoprecipitated MEP1A-speciﬁc DNA in TNF-α-treated cells as
compared to untreated cells (Fig. 5B).SS, day 0a DSS, day 3 DSS, day 7
.90 (8.88;10.40) 8.85 (8.58;9.23) 9.70 (8.90;10.20)
.30 (0.27;0.31) 0.31 (0.29;0.32) 0.33 (0.23;0.34)
1.70 (-6.02;0.65) -3.95 (-9.88;1.60) 1.45 (-2.95;4.79)
/6 1/6 1/6
/6 5/6 2/6
.5 (1.0;3.0) 3.0 (1.8;5.0) 2.0 (1.8;3.0)
.5 (1.5;3.3) 6.0 (4.0;8.0) 2.5 (1.8;5.0)
.5 (0;3.0) 5.0 (4.8;5.5) 3.5 (0.8;5.5)
dual animals.
Fig. 3. Differential expression of Cdx2 and Mep1a in proximal and distal colon in experimental colitis. qRT-PCR of Cdx2, Mep1a, and TNF-α mRNA levels in (A) proximal and
(B) distal colon of 4% DSS-treated BALB/cAcNTac mice relative to control mice (no DSS). Mice were killed by cervical dislocation on day 0, day 3, and day 7 after 5 days of DSS
exposure. Values were normalized to β-actin and ratios of Cdx2, Mep1a, or TNF-α to Ck20 (a marker of epithelial cells) mRNA levels in proximal and distal colon were compared
with untreated mice. Represented as medians (n=6 in each group), *pb0.05; **pb0.01 (Mann–Whitney U-test).
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Cytokines play a critical role in the pathogenesis of IBD, where their
expression might be highly elevated. The homeobox transcription
factor CDX2 is important for the intestinal homeostasis and may beFig. 4. Effect of pro-inﬂammatory cytokines and/or inﬂiximab on endogenous mRNA express
Caco-2 cells. Cells were treated for 24 h andmRNA levelsweremeasured by qRT-PCR. ThemRN
Values are represented as medians with interquartile ranges (n=8), **pb0.01; ***pb0.001 (Ma novel key factor for IBD pathogenesis [39]. Previous investigations
have shown a strong reduction in MEP1A expression in IBD patients,
and several polymorphisms in theMEP1A gene have been associated
with UC [12]. We have recently shown thatMEP1A is directly regulated
by CDX2 [19], and others have earlier reported that CDX2 expression isions in Caco-2 cells. (A) CDX2, (B) MEP1A, and (C) IL-8 mRNA in treated and untreated
A levelswere normalized to the level of RPLP0 and changes in expressionwere calculated.
ann–Whitney U-test).
Fig. 5. The effect of TNF-α on the CDX2 andMEP1A transcriptional activities and the in vivo binding of CDX2 to these regions. (A) Effect of TNF-α on the CDX2 and the MEP1A promoter
activities in Caco-2 cells. Cells were transiently transfectedwith the human CDX2 promoter, CDX2 promoter/enhancer,MEP1A promoter, or the GSK3β promoter construct (as a non-TNF-
α responsive control) followed by incubation with or without TNF-α for 24 h. Values are presented as relative to the promoter-less pGL4-Basic empty vector (EV) and presented as fold
induction. Signiﬁcant differences from the control (without TNF-α) values are shown (*pb0.05). (B) TNF-α suppresses the binding of CDX2 to the 5′ and 3′ regulatory elements of the
CDX2 gene and to theMEP1A promoter region. Immunoprecipitated DNA was analyzed by qPCR using gene speciﬁc primers with CDX2- and HA (negative control)-ChIP DNA from
Caco-2 cells pre-treated with or without TNF-α. Represented as medians with interquartile ranges (n=4), *pb0.05 (Mann–Whitney U-test).
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we hypothesized that cytokine-mediated regulation of CDX2may affect
theMEP1A expression.
In the present study, we have demonstrated thatMEP1A is regulated
by CDX2 and is dependent on CDX2 activity, supporting recent reports
by Boyd et al. [19]. We showed that the expression level of CDX2
mRNA and protein signiﬁcantly decreased during active stages of UC.
In accordance with a previous study, MEP1A mRNA expression was
similarly decreased in inﬂamed UC colon [12]. Immunohistochemical
analysis of CDX2 and the IEC marker CK20 showed that the decreased
CDX2 expression in activeUCpatientswas not due to a reduced number
of colonocytes. These observations supported a close relationship be-
tween CDX2 and MEP1A expression during intestinal inﬂammation
and interestingly, the expression pattern was inverse to the expression
pattern of TNF-α. Moreover, in the DSS-colitis model the mRNA
levels of Cdx2 and Mep1a in proximal and distal colon were found to
be differentially expressed. Although different mechanisms may exist
in the proximal and distal part of the colon, a possible explanation for
the discrepancy between the expression patterns might be that the
disease severity varies in different parts of the colon. The distal
part of the colon, is usually more severely affected by DSS treatment
than the proximal part, when evaluated by histopathology [40]. Thisobservation has indeed been supported by the expression patterns of
TNF-α measured in proximal and distal colon of mice challenged
with DSS, as the TNF-αmRNA in the distal colon remained high.
During active stages of IBD, the levels of pro-inﬂammatory cytokines
such as TNF-α and IFN-γ are up-regulated in the mucosa [41]. It was
revealed that Caco-2 cells in response to TNF-α had signiﬁcantly de-
creased endogenous CDX2 and MEP1A expression but not in response
to IFN-γ. The mRNA level of IL-8 was induced by both cytokines as
previously described [42], indicating an inﬂammatory state in the
cells. Our results suggest a major role for the cytokine TNF-α in the
suppression of CDX2 and MEP1A expression during inﬂammatory
conditions. Collectively, these data indicate that CDX2 and MEP1A
expression might be dependent on activity of UC and disease score
in mice and may correlate negatively with high levels of TNF-α.
TNF-α signals through multiple intracellular pathways. One of the
major signaling pathways used by TNF-α is that of nuclear factor (NF)-
κB [43], however, NF-κB must be further modiﬁed by phosphorylation
of its subunits for full activation. Several kinases including mitogen
activated protein kinases (MAPKs) have been implicated in this sec-
ondary modiﬁcation of NF-κB [44]. In Drosophila, the expressions of
antimicrobial peptides are regulated by a balance between Caudal
(homologues to human CDX2) and NF-κB [45]. Inhibition of Caudal
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alter the commensally bacteria population and causes apoptosis of
IECs. However, reintroducing the expression of Caudal restores a
healthy microbiota and normal host survival [45]. These studies further
suggest TNF-α and CDX2 expression combined to be involved in the
pathogenesis of IBD. Clearly, it will be interesting in the future to deﬁne
other factors that cooperate with CDX2 in regulatingMEP1A expression
in normal and inﬂamed gastrointestinal tissues.
We have shown that CDX2 is involved in the basal transcriptional
activity ofMEP1A gene promoter and we have previously reported that
the cis-element(s) responsible for the activity and auto-regulatory
mechanism of CDX2 gene expression was found in the 3′ enhancer re-
gion of CDX2 [19]. As a result the effect of TNF-α on CDX2 and MEP1A
promoter activities by reporter gene assayswas analyzed. In accordance
with themRNA results, reporter gene expressionmediated by the CDX2
orMEP1A promoter constructs signiﬁcantly decreased the luciferase ac-
tivity in cells pre-treated with TNF-α. These data suggested that TNF-α
impacts transcriptional activities of CDX2 and MEP1A genes. To further
elucidate the effect of TNF-α on CDX2 andMEP1A, ChIP was performed
in Caco-2 cells. ChIP assays revealed that, TNF-α treatment strongly
suppressed the recruitment of CDX2 to the 5′ and 3′ regions of the
CDX2 gene as well as to the MEP1A promoter region. These results
suggest that TNF-α inhibits CDX2 regulation by interfering with the
transcriptional activity and the DNA-binding of CDX2 protein. Thus,
the data are in agreement with a previous study, suggesting that TNF-α
represses CDX2 expression [28], and the present study, to our knowledge,
is the ﬁrst to report that TNF-α induces a down-regulation of MEP1A;
however, the mechanistic link remains unknown.
In addition to the ﬁndings reported in this study, we have recently
shown that shRNA-mediated CDX2 knock-down in Caco-2 cells
resulted in a 5-fold reduction in the MEP1A promoter activity and
more than 40% decrease of the endogenous MEP1A mRNA expression
[19]. Additionally, the expression of Mep1a has previously been
shown to be affected in Cdx2 conditional knock-out mice [9]. Thus,
these lines of evidence together with our ﬁndings in the present study
support the notion that CDX2-dependent MEP1A suppression by TNF-
α is one of the mechanisms underlying the decreased MEP1A ex-
pression observed in colitis. However, it is likely that other factors
contribute to the inhibitory effect displayed by TNF-α.
It has previously been shown that the expression ofMEP1A is depen-
dent on HNF4α expression, and an HNF4α binding site in the promoter
[46]. Furthermore, a markedly decreased Mep1a expression was found
in Hnf4α-null mice which exhibited increased susceptibility to DSS-
induced colitis [47]. We have previously shown a close relationship
between CDX2 and HNF4α regulation, as HNF4α is a direct target
gene of CDX2 and vice versa in Caco-2 cells [19,48]. It has also been
reported that TNF-α suppresses the expression of HNF4α through
NF-κB activation [49]. Thus, it is likely that cytokine-related inhibi-
tion of MEP1A expression might occur through repressing CDX2
and HNF4α transcription factors resulting in a deregulated MEP1A
transcription.
Intestinal inﬂammation is a complex process, involving the action
of a number of cytokines. Biological agents (such as IFX, adalimumab,
and certolizumab pegol) with anti-TNF-α antibodies have become an
important treatment option in IBD [31]. However, other TNF-α inhib-
itors such as etanercept have no effect in IBDwhichmight be due to yet
unknown kinetics that this biological agent is not transported to the in-
ﬂamed intestine. While TNF-α inhibitors are in widespread clinical use,
very little is known about the molecular and cellular effects of cytokine
blockade in human tissue. Our in vitro data showed that TNF-α blockade
with IFX induce a signiﬁcantly higher expression of CDX2 and MEP1A
by epithelial cells. Arijs and co-workers [50,51] have previously exam-
ined the gene expression proﬁle of IBD patients before and after IFX
treatment. Thus, when we extracted the CDX2 and MEP1A expression
proﬁle from the microarray data, both CDX2 and MEP1A gene expres-
sionswere signiﬁcantly up-regulated (pb0.01) in IFX treatedUCpatientsas compared to their baseline samples. In short, these observations indi-
cate that UC patients have signiﬁcant higher CDX2 and MEP1A colonic
gene expression levels after IFX treatment.
In summary, the present study demonstrates correlatively decreased
colonic CDX2 andMEP1A gene expression in inﬂamed mucosa. We have
revealed that TNF-α suppresses CDX2 and MEP1A expression and that
anti-TNF-α treatment with IFX recaptures the CDX2 and MEP1A gene
expression in vitro. Our results suggest that a TNF-α mediated down-
regulation of CDX2 might be responsible for the suppression ofMEP1A
expression and activity in intestinal inﬂammation. Therefore, these
data presented indicate, that a dysfunction of CDX2 couldmake a pivot-
al contribution to the pathogenesis of IBD, especially in the colon.
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